期刊文献+

a-(1→2)-甘露糖三糖的合成

Synthesis of a-(1→2)-Mannotrisacchride
原文传递
导出
摘要 目的利用化学方法高效合成PI-88糖基片段a-(1→2)-甘露糖三糖。方法以4,6位苯亚甲基保护的D-甘露糖硫苷3为原料合成N-对甲苯磺酰亚胺酯供体6,以TMSOTf作为促进剂,供体6与受体3进行糖苷化反应,得到a-(1→2)甘露糖二糖7,然后将二糖脱除苯甲酰基,再次与供体6进行糖苷化反应,合成出糖基片段a-(1→2)甘露糖三糖2。结果以85%和79%的糖苷化反应产率,得到a-(1→2)甘露糖二糖7和三糖2,为PI-88构效关系的研究提供物质基础和保障。 Objective An efficient synthesis of a-(1→2)-mannotrisacchride was achieved.The target was designed to mimic the promising anticancer agent PI-88.Method The glycosyl N-tosyl benzimidate 6was prepared from phenyl 4,6-O-benzylidene-3-O-(2-naphthylmethyl)-1-thio-a-D-mannopyranoside 3.The analogue 7was obtained from the glycosyl N-tosyl benzimidate 6with acceptor 8in the presence of TMSOTf at 0 ℃ and removal of benzoyl groups in 7to obtain acceptor 8,then 8reacted with 6to give trisaccharide 2.Results The desired mannose disacchride 7and trisaccharide 2were obtained in 85%and79% glycosidic yield,which was valuable for studying the structure and activity relationship of PI-88.
出处 《中国海洋药物》 CAS CSCD 2015年第6期69-74,共6页 Chinese Journal of Marine Drugs
基金 国家自然科学基金项目(21272220) 山东省科技发展计划项目(2012GHY11526)资助
关键词 a-(1→2)-甘露糖三糖 硫苷 N-对甲苯磺酰亚胺酯 糖苷化 a-(1→2)-Mannotrisacchride Thiolglycoside donor N-tosyl benzimidate Glycosylation
  • 相关文献

参考文献19

  • 1Ferro V, Li C, Fewings K, et al. Determination of the com- position of the oligosaccharide phosphate fraction of Pichia (Hansenula) holstii NRRL Y-2448 phosphomannan by cap- illary electrophoresis and HPLC [J]. Carbohydr Re. 2002, 337: 139-146. 被引量:1
  • 2Yu G, Gunay N S, Linhardt R J, et al. Preparation and an- ticoagulant activity of the phosphosulfomannan PI-88 [J]. Eur J Med Chem. 2002, 37: 783-791. 被引量:1
  • 3Parish C R, Freeman C, Brown K J, et al. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity [J]. Cancer Res. 1999, 59.. 3433- 344l. 被引量:1
  • 4Iversen P O, Sorenson D R, Benestad H B, Inhibitors of an- giogenesis selectively reduce the malignant cell load in ro- dentmodels of human myeloid leukemias [J]. Leukemia 2002, 16: 376-381. Ng,2011, 6 (2): 131-133. 被引量:1
  • 5Liu C J, Lee P H, Lin D Y, et al. Heparanase inhibitor PI- 88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage [J]. J Hepatol. 2009, 50: 958-968. 被引量:1
  • 6贾晋斌,倪淑欣.肝癌治疗新药临床研究进展[J].中国医药生物技术,2011,6(2):131-133. 被引量:9
  • 7Wall D, Douglas S, Ferro V, et al. Characterisatlon of the anticoagulant properties of a range of structurally diverse sulfated oligosaccharides [J]. ThrombRes, 2001, 103: 325- 335. 被引量:1
  • 8Nyberg K, Ekblad M, Bergstrom T, et al. The low molecu- lar weight heparan sulfate-mimetic, PI-88, inhibits cell-to- cell spread of herpes simplex virus [J]. Antiviral Res. 2004, 63: 15-24. 被引量:1
  • 9Adams Y, Freeman C, Schwartz-Albiez R, et al. Inhibition of Plasmodiura falciparum growth in vitro and adhesion to chondroitin-4-sulfate by the heparan sulfate mimetic PI-88 and other sulfated oligosaccharides [J]. Antimicrob. Agents Chemother. 2006, 50: 2850-2852. 被引量:1
  • 10Gu G F, Wei G H, Du Y G. Synthesis of a 6V-sulfated mannopentasaccharide analogue related to PI-88 l-J]. Car-bohydrRes. 2004, 339: 1155-1162. 被引量:1

二级参考文献16

  • 1赵超尘,李君,王平,王学浩.酪丝亮肽治疗手术不能切除的原发性肝癌临床疗效观察[J].中国现代医学杂志,2007,17(3):357-359. 被引量:8
  • 2O'Brien K, Cokkinides V, Jemal A, et al. Cancer statistics for Hispanics, 2003. CA Cancer J Clin, 2003, 53(4):208-226. 被引量:1
  • 3Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 2008, 359(4):378-390. 被引量:1
  • 4Cheng A, Kang Y, Chen Z, et al. Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma. J Clin Oncol, 2008, 26(20 Suppl):4509. 被引量:1
  • 5Hossain MM, Hosono-Fukao T, Tang R, et al. Direct detection of HSulf-1 and HSulf-2 activities on extracellular heparan sulfate and their inhibition by PI-88. Glycobiology, 2010, 20(2): 175-186. 被引量:1
  • 6Kudchadkar R, Gonzalez R, Lewis KD. PI-88: a novel inhibitor of angiogenesis. Expert Opin Investig Drugs, 2008, 17(11):1769-1776. 被引量:1
  • 7Liu CJ, Lee PH, Lin DY, et al. Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage. J Hepatol, 2009, 50(5):958-968. 被引量:1
  • 8A Service of the U.S. National Institutes of Health. Phase Ⅲ Study of PI-88 in Post-Resection Hepatocellular Carcinoma (PATHWAY), NCT00568308. (2008-07-22) [2011-02-25]. http://www.clinicaltrials. gov/ct2/show/NCT00568308?term=NCT00568308&rank= 1. 被引量:1
  • 9A Service of the U.S. National Institutes of Health. Soratemb as Adjuvant Treatment in the Prevention of Recurrence of Hepatocellular Carcinoma (STORM), NCT00692770. (2011-01-24) [2011-02-25]. http://www.clinicaltrials.gov/ct2/show/NCT00692770?term=NCT006 92770&rank=l. 被引量:1
  • 10Lu R, Jia J, Bao L, et al. Experimental study of the inhibition of human hepatocarcinoma BEL7402 ceils by the tripeptide tyroserleutide(YSL). Cancer Chemother Pharmacol, 2006, 57(2):248- 256. 被引量:1

共引文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部